A Retrospective Analysis of Lobeglitazone as an Add-On to Existing Glucose-Lowering Therapy in Indian Adults with Suboptimally Controlled Type 2 Diabetes for Its Clinical Effectiveness: A Real-World Clinical Experience

被引:0
作者
Baidya, Arjun [1 ]
Ahmed, Rishad [2 ]
Bera, Mridul [3 ]
Gupta, Amit [4 ]
Guha, Mridul Kumar [5 ]
机构
[1] Nil Ratan Sircar Med Coll & Hosp, Dept Endocrinol, Kolkata, India
[2] KPC Med Coll & Hosp, Dept Med, Kolkata, India
[3] NH Narayana Multispecial Hosp, Howrah, W Bengal, India
[4] GD Diabet & Res Inst, Kolkata, W Bengal, India
[5] Apollo Clin, Kolkata, W Bengal, India
来源
CLINICAL DIABETOLOGY | 2024年
关键词
lobeglitazone; thiazolidinediones; type; 2; diabetes; FLUID RETENTION; BLADDER-CANCER; THIAZOLIDINEDIONES; PIOGLITAZONE; METFORMIN; RISK;
D O I
10.5603/cd.101191
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The objective of the current study was to evaluate the safety and effectiveness of lobeglitazone as an add-on therapy in suboptimally controlled Indian type 2 diabetes (T2D) patients in a real-world clinical setup.<br /> Materials and methods: The study was conducted in suboptimally controlled T2D patients while being treated with lobeglitazone once daily (0.5 mg) as an add-on to existing glucose-lowering agents in various clinics in eastern India.<br /> Results: The patients' average body weight was 80.78 +/- 9.36 kg, with a body mass index (BMI) of 30.86 +/- 4.16 kg/m2. The addition of lobeglitazone 0.5 mg to existing therapy over 12 weeks resulted in a statistically significant HbA1c reduction (-1.1 +/- 0.72, p < 0.005). Among all 4 groups, similar glycemic declines were observed with no major intergroup variation (p = 0.074). Also, there was a statistically significant mean drop in both postprandial plasma glucose (-71.47 +/- 26.73, p < 0.005) and fasting plasma glucose (FPG) (-47.11 +/- 21.45, p < 0.005). It was found that a patient's BMI was significantly linked to their likelihood of meeting their recommended target HbA1c (57.3% in BMI 25-30 vs. 34% in BMI > 30, p = 0.0233) and target FPG (59% in BMI 25-30 vs. 45.3% in BMI > 30, p = 0.0112). Among the total population, 35 (9.61%) patients reported hypoglycemia, and no one required medical assistance. Conclusions: In suboptimally controlled diabetes patients, in combination with one or more commonly prescribed antidiabetic drugs, lobeglitazone significantly improved the glycemic and non-glycemic measures and was well tolerated.
引用
收藏
页码:274 / 281
页数:8
相关论文
共 30 条
[21]   Tolerability and Pharmacokinetics of Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor-γ Agonist, After a Single Oral Administration in Healthy Female Subjects [J].
Park, Min Kyu ;
Kim, Tae-Eun ;
Kim, JaeWoo ;
Kim, Chin ;
Yoon, Seo Hyun ;
Cho, Joo-Youn ;
Jang, In-Jin ;
Yu, Kyung-Sang ;
Lim, Kyoung Soo .
CLINICAL DRUG INVESTIGATION, 2014, 34 (07) :467-474
[22]   Epidemiology of type 2 diabetes in India [J].
Pradeepa, Rajendra ;
Mohan, Viswanathan .
INDIAN JOURNAL OF OPHTHALMOLOGY, 2021, 69 (11) :2932-2938
[23]   Thiazolidinediones: effects on insulin resistance and the cardiovascular [J].
Quinn, C. E. ;
Hamilton, P. K. ;
Lockhart, C. J. ;
McVeigh, G. E. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (04) :636-645
[24]   The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity [J].
Rocha, Ruth F. ;
Rodrigues, Tiago ;
Menegatti, Angela C. O. ;
Bernardes, Goncalo J. L. ;
Terenzi, Hernan .
BIOORGANIC CHEMISTRY, 2020, 100
[25]   Thiazolidinediones and heart failure - A teleo-analysis [J].
Singh, Sonal ;
Loke, Yoon K. ;
Furberg, Curt D. .
DIABETES CARE, 2007, 30 (08) :2148-2153
[26]   Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure [J].
Tang, WHW ;
Francis, GS ;
Hoogwerf, BJ ;
Young, JB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (08) :1394-1398
[27]   Pioglitazone use and risk of bladder cancer: population based cohort study [J].
Tuccori, Marco ;
Filion, Kristian B. ;
Yin, Hui ;
Yu, Oriana H. ;
Platt, Robert W. ;
Azoulay, Laurent .
BMJ-BRITISH MEDICAL JOURNAL, 2016, 352
[28]   Type 2 diabetes in South Asians compared to Europeans: Higher risk and earlier development of major cardiovascular events irrespective of the presence and degree of retinopathy. Results from The HinDu The Hague Diabetes Study [J].
van Niel, Judith ;
Geelhoed-Duijvestijn, Petronella H. L. M. ;
Numans, Mattijs E. ;
Kharagjitsing, Aan V. ;
Vos, Rimke C. .
ENDOCRINOLOGY DIABETES & METABOLISM, 2021, 4 (03)
[29]  
Vasudevan Abu R, 2004, Diabetes Technol Ther, V6, P850, DOI 10.1089/dia.2004.6.850
[30]   Drug therapy: Thiazolidinediones [J].
Yki-Jarvinen, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (11) :1106-1118